Toremifene (Fareston): risk of QT prolongation

Toremifene (fareston) is associated with a dose-dependent risk of QT prolongation.

Article date: February 2009

Toremifene (fareston) is an oestrogen receptor antagonist. Currently it is not widely used in the UK, but remains a licensed option to treat hormone-dependent metastatic breast cancer in postmenopausal women.

A European assessment has concluded that toremifene is associated with a dose-dependent risk of increase in QT interval, which carries a risk of serious cardiac arrhythmia. The summary of product characteristics has been updated to include new contraindications and warnings. Do not prescribe toremifene with other drugs that prolong the QT interval.

To view updated product information, press release, and question and answer document, see the European Medicines Agency website

 

Article citation: Drug Safety Update February 2009, vol 1 issue 7: 7a.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.